What is continuous glucose monitoring?

Continuous glucose monitoring (CGM) is a method of tracking blood glucose (blood sugar) levels automatically and continuously throughout the day and night. A small sensor worn on the body measures glucose in the fluid between cells (interstitial fluid) every one to five minutes and transmits the data wirelessly to a receiver, smartphone, or smartwatch.

Unlike traditional blood glucose meters that require a finger-stick blood sample to get a single reading, CGM provides a continuous stream of data — showing not just where your glucose is right now, but where it has been over the past hours, and trend arrows that indicate where it is heading.

Key point

CGM does not measure glucose in the blood directly. It measures glucose in interstitial fluid — the fluid surrounding cells in tissue just below the skin. This is closely correlated with blood glucose but typically lags blood glucose by 5–15 minutes, which is important to understand when interpreting readings.

288
Glucose readings per day from a typical CGM device
14
Days of wear per sensor for most current CGM devices
70%
Reduction in severe hypoglycemia reported with CGM use

How does CGM work?

A CGM system has three main components that work together to deliver continuous glucose data to the user.

1

The sensor

A small, flexible filament — typically 5–7mm long and thinner than a human hair — is inserted just below the skin surface, usually on the abdomen or upper arm. The sensor contains an enzyme (glucose oxidase) that reacts with glucose in the interstitial fluid and generates a tiny electrical current proportional to the glucose concentration. This electrochemical signal is the raw glucose measurement.

2

The transmitter

Attached to the sensor, the transmitter reads the electrical signal from the sensor, applies calibration algorithms, converts it to a glucose value in mg/dL or mmol/L, and transmits the data wirelessly via Bluetooth to a display device. Transmitters are either integrated into disposable sensors or reusable components that attach to each new sensor.

3

The receiver / app

The glucose data is received by a dedicated receiver, smartphone app, or smartwatch. The display shows the current glucose value, a trend arrow indicating direction and rate of change, a graph of recent glucose history, and alerts when glucose goes out of the user's target range. Data can be shared with family members or healthcare providers in real time.

Most modern CGM sensors last 10–15 days before requiring replacement. Insertion is done with a small applicator device — the process takes seconds and causes minimal discomfort for most users. After a warm-up period of one to two hours, the sensor begins delivering readings.

CGM vs traditional blood glucose monitoring

Traditional self-monitoring of blood glucose (SMBG) using a finger-stick meter has been the standard for decades. CGM does not fully replace it in all situations, but provides a fundamentally different and richer picture of glucose patterns.

Feature CGM Finger-stick meter
Readings per day 288 (every 5 min) 4–8 (manual)
Trend information Yes — direction and rate No — single snapshot
Overnight monitoring Continuous, with alerts Not practical
Finger-stick required No (most devices) Every reading
Real-time alerts Yes — high and low alerts No
Data sharing Real-time to caregivers Manual log only
Cost Higher (sensor subscription) Lower upfront
Accuracy in rapid change May lag by 5–15 min Immediate blood value
When finger-sticks still matter

Even with CGM, finger-stick verification is recommended when CGM readings seem inconsistent with symptoms, before making critical treatment decisions (such as insulin dosing in some circumstances), and when CGM indicates rapidly changing glucose. Always follow your healthcare provider's guidance on when to verify with a finger-stick.

Benefits of continuous glucose monitoring

The clinical evidence for CGM benefits in people with diabetes is substantial and growing. Beyond diabetes management, CGM is revealing new insights about metabolic health in broader populations.

📉
Improved A1C
Multiple randomized controlled trials show CGM use reduces HbA1c by 0.3–1.0 percentage points in people with Type 1 and Type 2 diabetes, compared to standard glucose monitoring.
🛡️
Reduced hypoglycemia
CGM alerts warn users before glucose drops to dangerous levels. Studies report 40–70% reductions in time spent in hypoglycemia, including during sleep when symptoms may not wake the user.
🎯
More time in range
CGM users consistently spend more time with glucose in the target range (70–180 mg/dL). Time in range is now recognized as a clinically meaningful outcome measure alongside A1C.
😴
Overnight safety
Nocturnal hypoglycemia is a significant risk for insulin users. CGM provides continuous overnight monitoring with configurable low glucose alarms that wake the user or alert caregivers.
🍽️
Food response insights
CGM reveals how different foods, meal timing, portion sizes, and food combinations affect glucose — enabling personalized dietary adjustments that no other tool can provide at this resolution.
🏃
Exercise optimization
Glucose responses to exercise vary significantly between individuals and exercise types. CGM enables real-time monitoring during physical activity to optimize performance and prevent exercise-induced hypoglycemia.
Medical disclaimer

The benefits described above are based on published clinical research in specific patient populations. Individual results vary. CGM is a monitoring tool, not a treatment. Any changes to your diabetes management — including insulin dosing, medication, or diet — should be made in consultation with your healthcare provider.

Who should use CGM?

CGM was originally developed for people with Type 1 diabetes who require intensive insulin therapy. Its indications have expanded substantially and it is now used across a much broader population.

💙
Type 1 diabetes
CGM is now considered standard of care for most people with Type 1 diabetes. The combination of real-time data, trend arrows, and alerts — particularly overnight — provides safety and control that finger-stick monitoring cannot match. Most clinical guidelines recommend CGM for all Type 1 patients who can use the technology.
🩺
Type 2 diabetes
CGM is increasingly recommended for people with Type 2 diabetes, particularly those using insulin. Evidence shows improved glycemic control and reduced hypoglycemia. Medicare coverage for Type 2 basal insulin users was expanded significantly, making CGM accessible to a much larger population.
⚠️
Prediabetes
For people with prediabetes, CGM can postprandial glucose spikes that standard A1C testing misses. Understanding which foods trigger elevated glucose responses enables targeted dietary interventions that may slow or prevent progression to Type 2 diabetes.
Health optimization
CGM use among people without diabetes has grown rapidly, driven by interest in metabolic health, longevity, and performance optimization. OTC CGM devices now available without a prescription have made this segment accessible. The evidence base for CGM benefit in non-diabetic populations is still developing.

How accurate is CGM?

CGM accuracy is measured using Mean Absolute Relative Difference (MARD) — the average percentage difference between CGM readings and simultaneous blood glucose measurements. Lower MARD indicates higher accuracy.

Current generation CGM devices from major manufacturers achieve MARD values of 8–10%, compared to approximately 5% for a high-quality finger-stick meter. This means CGM readings are clinically accurate for most diabetes management decisions, though individual readings may differ from blood glucose by up to 15–20% in some circumstances.

Factors that affect CGM accuracy

Rapid glucose changes: Because CGM measures interstitial glucose, it lags blood glucose by 5–15 minutes during periods of rapid change — such as during or after eating, during intense exercise, or during hypoglycemia. Trend arrows help compensate for this lag.

Sensor warm-up: The first 1–2 hours after sensor insertion may show reduced accuracy as the sensor stabilizes in the tissue. Most devices display a warm-up countdown and do not provide readings during this period.

Sensor placement: Accuracy can vary by body site. Follow manufacturer guidelines for approved insertion sites and rotate locations to avoid tissue buildup that may reduce sensor performance.

Certain medications: Some medications, including high-dose acetaminophen (paracetamol), can interfere with CGM accuracy. Check the device's prescribing information for a complete list of potential interferences.

How to get started with CGM

For people with diabetes

Talk to your endocrinologist, diabetes care specialist, or primary care provider. CGM devices are prescription medical devices in most countries. Your healthcare provider can assess whether CGM is appropriate for your situation, prescribe the right device, and help you interpret your data in the context of your treatment plan. Insurance coverage varies — your provider's office can help navigate coverage requirements.

For health optimization without diabetes

Several CGM devices are now available over the counter without a prescription in the United States, including Abbott's Lingo and Dexcom's Stelo — both approved for adults without diabetes. These devices are available directly from manufacturers and major pharmacies. They provide the same continuous glucose data but are positioned as wellness tools rather than medical devices.

Important

If you have diabetes or any other medical condition, do not start using a CGM device or make changes to your treatment based on CGM data without first consulting your healthcare provider. CGM data requires clinical context to interpret safely and act upon.

What to expect

Most new CGM users go through a learning curve. The volume of data — up to 288 readings per day — can be overwhelming at first. Focus on patterns rather than individual readings. Look at overnight glucose stability, post-meal responses to specific foods, and how exercise affects your levels. Most CGM apps provide pattern summaries that make this easier over time.

Frequently asked questions

Does inserting a CGM sensor hurt?
Most users report minimal discomfort during sensor insertion. The applicator devices used by current CGM systems insert the sensor filament quickly, and most people describe it as a brief pinch or pressure rather than pain. The sensor filament is extremely thin — much thinner than a finger-stick lancet. Discomfort during wear is uncommon; some users experience mild itching under the adhesive patch.
Can I shower, swim, or exercise with a CGM?
Yes. Current CGM sensors from major manufacturers are waterproof and rated for swimming and showering. Most are rated to a depth of 2.4–2.7 meters (8 feet) for up to 24–30 minutes. Exercise with CGM is not only possible but one of the most valuable use cases — seeing real-time glucose responses during physical activity provides insights unavailable any other way. Always check your specific device's water resistance rating.
How much does CGM cost?
CGM costs vary significantly by device, country, and insurance coverage. In the US, prescription CGM systems (Dexcom G7, Abbott FreeStyle Libre 3) cost approximately $100–$150 per month for sensors with insurance coverage for eligible patients. Without insurance, costs can reach $300–$400/month. OTC CGM devices for wellness use (Dexcom Stelo, Abbott Lingo) are priced at approximately $89–$99 for a one-month supply as of 2026. Coverage is expanding — Medicare and many private insurers now cover CGM for Type 1 and insulin-using Type 2 patients.
Do I still need to do finger-stick tests if I use CGM?
For most day-to-day CGM use, finger-sticks are not required. However, clinical guidelines recommend verifying CGM readings with a finger-stick before making critical treatment decisions when symptoms do not match the CGM reading, during the sensor warm-up period, and in certain other situations specified by your healthcare provider. Always follow your provider's guidance rather than relying on CGM readings alone for insulin dosing or other treatment decisions.
What is "time in range" and why does it matter?
Time in range (TIR) is the percentage of time glucose levels spend within a target range — typically 70–180 mg/dL for most people with diabetes. It is emerging as a key outcome measure alongside HbA1c because it captures glucose variability and hypoglycemia burden that A1C misses. International consensus guidelines recommend a TIR target of greater than 70% for most adults with diabetes. CGM is the only practical way to measure time in range — traditional finger-stick monitoring cannot provide this metric reliably.